HHS Contract Pharmacy Advisory Opinion Author Returns to Private Sector

Former HHS General Counsel Robert Charrow, who wrote the Dec. 30 advisory opinion on 340B contract pharmacy, has rejoined his law firm.

Robert Charrow—the U.S. Health and Human Services (HHS) general counsel who memorably opined that drug companies must offer their products at or below the 340B ceiling price “be it the lunar surface, low-earth orbit, or a neighborhood pharmacy”—has rejoined his

Read More »

Ex-HRSA Administrator Wakefield Back at HHS, Hospital Association Exec Joins Too

Former HRSA Administrator Mary Wakefield is back at HHS, serving as counselor to Secretary Xavier Becerra.

Mary Wakefield, who led the U.S. Health Resources and Services Administration (HRSA) from 2009 to 2015, is back at HHS.

HHS announced Tuesday that Wakefield accepted an appointment to serve as counselor to HHS Secretary Xavier Becerra. She served

Read More »

PhRMA Sues to Block Medicaid Best Price Change

PhRMA is challenging a CMS Medicaid prescription drug best price rule that it says "will harm patients and manufacturers alike." | Shutterstock

Pharmaceutical Research and Manufacturers of America (PhRMA) has asked a federal judge to invalidate a federal regulation that would require drug makers, starting in January 2023, to include the full value of patient financial assistance in their Medicaid best price

Read More »

New Developments in 340B Contract Pharmacy Lawsuits

Federal judges yesterday issued orders in four lawsuits over 340B program contract pharmacy policy.

Federal courts in Delaware, Indiana, and New Jersey yesterday issued orders related to the federal government’s May 17 demand to six drug manufacturers to immediately resume unrestricted 340B pricing on drugs shipped to contract pharmacies.

The government last week

Read More »

Brooks-LaSure Poised to be Confirmed as CMS Administrator

The U.S. Senate is expected today to approve Chiquita Brooks-LaSure's nomination to be CMS Administrator.

The U.S. Senate is expected today to confirm Chiquita Brooks-LaSure’s nomination to be Administrator of the Centers for Medicare & Medicaid Services (CMS), clearing the way for the swearing in of another key Biden administration official with influence touching on

Read More »

Breaking News

BREAKING: Developments in Multiple 340B Contract Pharmacy Lawsuits

Eli Lilly and Sanofi yesterday filed court papers in response to HRSA's 340B contract cease and desist letters. Novo Nordisk is expected to follow suit. There could be a decision on AstraZeneca's motions as soon as tonight. | Shutterstock

Drug manufacturers Eli Lilly and Sanofi late yesterday asked federal judges for temporary protection from federal health agency orders to immediately resume offering 340B pricing on drugs shipped to contract pharmacies. Drug maker Novo Nordisk is expected to seek similar

Read More »

BREAKING: Developments in AstraZeneca’s 340B Lawsuit

AbbVie and AstraZeneca filed a pair of lawsuits to block Minnesota's law barring manufacturer 340B contract pharmacy restrictions.

A federal district judge in Wilmington, Del., this morning gave the federal government until 11:00 a.m. Eastern tomorrow to respond to AstraZeneca’s emergency motion yesterday for a stay in its lawsuit over the government’s efforts to compel it to resume

Read More »

Drugmakers Show No Sign So Far of Giving in to HRSA on 340B Contract Pharmacy

So far, drug manufacturers have shown no sign of obeying HRSA's order to resume 340B pricing without regard to how drugs are dispensed. | Shutterstock

Six drug companies have shown no sign so far of acquiescing to the federal government’s order on Monday to immediately resume 340B pricing on their products dispensed by contract pharmacies.

340B covered entities yesterday reported seeing no evidence that Eli

Read More »

Health Centers, HIV/AIDS Clinics, and Feds Agree on Keeping Stays in Place in 340B Lawsuits

In separate status reports to a federal judge last night, health centers and the government, and HIV/AIDS clinics and the government, agreed to keep stays in place in lawsuits involving 340B contract pharmacy. | Shutterstock

The National Association of Community Health Centers (NACHC) and the U.S. Justice Department (DOJ) last night proposed that a federal district judge should maintain the stay in NACHC’s suit against the government stemming from drug manufacturers’ denials of 340B pricing

Read More »

AbbVie Abused Humira’s Orphan Drug Designation, House Panel Says

Rep. Carolyn Maloney (D-N.Y) on Tuesday asked the FTC to investigate whether AbbVie's pricing and business practices broke the law.

A U.S. House committee alleged Tuesday that AbbVie gamed the federal orphan drug program to boost profits for its anti-inflammatory drug Humira—by far, the top-selling medicine in the United States.

Four types of hospitals that participate in the 340B program

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live